The inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various agonists in guinea pig and human airways: comparison with pinacidil and verapamil.
The effects of the potassium channel activators, cromakalim, BRL 38227 and pinacidil, and the calcium antagonist, verapamil, have been compared against various spasmogens on airway responses in vitro and in vivo in the guinea pig and also in human isolated bronchi. In guinea pig tracheal spirals, potassium channel activators generally had a greater inhibitory effect than verapamil against tone induced by a wide range of spasmogens (spontaneous, 5-hydroxytryptamine, leukotriene D4, prostaglandin E2). The potassium channel activators had very little effect against potassium chloride- and carbachol-induced tone in guinea pig tracheal spirals [e.g., cromakalim (20 microM) induced relaxations of 0.21 +/- 0.03 (relative to an isoprenaline maximum = 1.0, mean +/- S.E.M.) against carbachol, compared to 0.77 +/- 0.03 against histamine]. In vivo, the potassium channel activators prevented histamine and 5-hydroxytryptamine-induced bronchoconstrictions, but had little inhibitory effect against acetylcholine. In contrast, in human bronchi, cromakalim was capable of inducing powerful concentration-dependent relaxations against carbachol-induced tone [cromakalim (20 microM) induced relaxations of 0.77 +/- 0.09 (relative to isoprenaline = 1.0, mean +/- S.E.M.) against carbachol, compared to 0.95 +/- 0.04 against histamine]. In human bronchi, all the inhibitory agents were more potent and more effective, except that verapamil did not have an increased maximum response. We conclude that potassium channel activators should be effective at relaxing contractions induced by a wide range of spasmogens in man.
Taylor
S G
SG
SmithKline Beecham Pharmaceuticals, Biosciences Research Centre, Epsom, Surrey, England.
Arch
J R
JR
Bond
J
J
Buckle
D R
DR
Shaw
D J
DJ
Taylor
J F
JF
Ward
J S
JS
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects*; D001986:Bronchial Spasm / Q000139:chemically induced / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000494:pharmacology*; D002217:Carbachol / Q000494:pharmacology; D019806:Cromakalim; D004347:Drug Interactions; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology*; D013237:Stereoisomerism; D014132:Trachea / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology*
D001578:Benzopyrans; D001993:Bronchodilator Agents; D006146:Guanidines; D015221:Potassium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim; D020110:Pinacidil; D002217:Carbachol; D014700:Verapamil